A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

NCT00144053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Cisplatin+Vindesine+MMC/ concurrent radiation
DRUG: Irinotecan+Carboplatin/concurrent radiation
DRUG: Paclitaxel+Carboplatin/concurrent radiation

Sponsor

West Japan Thoracic Oncology Group